Company intelligence / Profile preview
Forlong Biotechnology
Suzhou, Jiangsu, Chinaforlongbiotech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead program FL115 (an IL-15 superagonist) demonstrated good safety and initial efficacy as monotherapy and in combination with checkpoint inhibitors in Phase 1 studies for advanced solid tumors in the US and China, including achieving partial responses as monotherapy. Combo studies with anti-PD-1 and with BCG in NMIBC currently advancing to Phase 2. Preclinical pipeline assets (FL116, FL117, FL118) show tumor-killing activity in resistant models.
- Therapeutic areas
- Oncology
- Modalities
- ProteinRecombinant proteinFusion proteinAntibodyCytokineBiologic
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Shell BioTechHenliusThird-party licensee (unnamed, China IND for Fbody fusion protein)
Beyond the preview
Go deeper on Forlong Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Forlong Biotechnology.